Circular RNA circVAPA promotes chemotherapy drug resistance in gastric cancer progression by regulating miR-125b-5p/STAT3 axis

Figure 3 Elevation of CircVAPA enhances chemotherapy drug resistance of gastric cancer cells. A: The expression of circVAPA, STAT3, Survivin, Mcl-1, and Bcl-xl was measured by qPCR in the SGC7901 and SGC7901/cisplatin (DDP) cells; B: STAT3 phosphorylation and levels of STAT3, Survivin, Mcl-1, and Bcl-xl were tested by Western blot analysis; C: SGC7901/DDP cells were initially treated with DDP at indicated doses and then with control shRNA or circVAPA shRNA. Cell viability was analyzed by MTT assay; D: SGC7901/DDP cells were treated with DDP or co-treated with DDP and circVAPA shRNA. Cell apoptosis was analyzed by flow cytometry. Data are presented as the mean ± SD. ^aP < 0.05.